Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibitors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Erectile dysfunction
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Dec 2012 New source identified and integrated (German Clinical Trials Register record: DRKS00004118).
- 01 Sep 2011 Results published in the Journal of Sexual Medicine.
- 02 Feb 2010 Actual patient number (159) added as reported by ClinicalTrials.gov.